The University of Florida Health Cancer Center has appointed two accomplished oncologists to key executive leadership roles. The appointments will position the center to reach even greater heights in cancer research and care after achieving designation from the National Cancer Institute, or NCI, in June.
Thomas George, M.D., FACP, a distinguished clinician and clinical investigator who has served as the inaugural associate director for clinical research at the Cancer Center since 2016, has been named deputy director. George, a professor in the division of hematology and oncology in the UF College of Medicine who specializes in gastrointestinal cancers and early-phase cancer drug development, assumes the position after John R. Wingard, M.D., retired in July after 27 years at UF.
Paul Crispen, M.D., a urologic oncologist, has been named associate director for clinical research. Crispen, a professor in the department of urology, has extensive experience with clinical trials. From 2017 to 2022, he served as the founding chair of the Cancer Center’s Scientific Review and Monitoring Committee, which provides critical peer review of cancer-relevant studies at UF before they are activated.
To learn more please visit https://bit.ly/3O0FPjn.
